These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31156852)

  • 1. Economic analysis of not running tenders for recombinant Factor VIII procurement: a simplified analysis to estimate an otherwise unknown pharmacoeconomic index.
    Maratea D; Fadda V; Trippoli S; Messori A
    Eur J Hosp Pharm; 2016 Jul; 23(4):219-223. PubMed ID: 31156852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenders for the Procurement of Medical Devices: Adapting Cost-Effectiveness Rules to the Requirements of the European Public Procurement Directive.
    Messori A; Trippoli S; Caccese E; Marinai C
    Ther Innov Regul Sci; 2020 Jan; 54(1):226-231. PubMed ID: 32008234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
    Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 9. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.
    Hockenhull J; Elremeli M; Cherry MG; Mahon J; Lai M; Darroch J; Oyee J; Boland A; Dickson R; Dundar Y; Boyle R
    Health Technol Assess; 2012; 16(12):III-IV, 1-110. PubMed ID: 22409877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
    Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
    Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Corticosteroid Nasal Spray vs Surgical Therapy in Patients With Severe to Extreme Anatomical Nasal Obstruction.
    Teti VP; Akdagli S; Most SP
    JAMA Facial Plast Surg; 2016 May; 18(3):165-70. PubMed ID: 26747790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analyses of sacubitril-valsartan for heart failure.
    Liu XQ; He LS; Huang JQ; Xiong LJ; Xia C; Lao HY
    Heart Fail Rev; 2021 Sep; 26(5):1119-1130. PubMed ID: 32405811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
    Connock M; Juarez-Garcia A; Frew E; Mans A; Dretzke J; Fry-Smith A; Moore D
    Health Technol Assess; 2006 Jun; 10(20):iii-iv, ix-113. PubMed ID: 16729919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the cost-effectiveness of pay-for-performance in primary care in the UK.
    Pandya A; Doran T; Zhu J; Walker S; Arntson E; Ryan AM
    BMC Med; 2018 Aug; 16(1):135. PubMed ID: 30153827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
    Zueger PM; Schultz NM; Lee TA
    Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.